Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 2.1
5-Year Impact Factor – 2.2
Scopus CiteScore – 3.4 (CiteScore Tracker 3.7)
Index Copernicus  – 161.11; MNiSW – 70 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2017, vol. 26, nr 6, September, p. 987–990

doi: 10.17219/acem/63095

Publication type: original article

Language: English

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

Rheumatoid factor and anti-cyclic citrullinated peptide (anti-CCP) antibodies with hepatitis B and hepatitis C infection: Review

Orhan Zengin1,A,B,C,D, Hamit Yıldız2,D, Zeynep Hanım Demir3,D, Muhammed Sait Dağ4,D, Musa Aydınlı4,D, Ahmet Mesut Onat5,D, Bünyamin Kısacık5,A,D

1 Faculty of Medicine, Gaziantep University, Turkey

2 Department of İnternal Medicine, School of Medicine, Gaziantep University, Turkey

3 NYU School of Medicine, Center for Cognitive Neurology, New York, the USA

4 Department of Gastroenterology, School of Medicine, Gaziantep University, Turkey

5 Department of Rheumatology, School of Medicine, Gaziantep University, Turkey

Abstract

Background. Viruses are common and are involved in the etiology of idiopathic rheumatological diseases. Hepatitis B virus (HBV), a member of the family Hepadnaviridae and hepatitis C virus (HCV), play an important role in the undetermined etiology of arthritis. The clinical manifestations of hepatitis B and C show similarities with various diseases, such as rheumatic diseases. Anti-cyclic citrullinated peptide (anti-CCP) is a specific serological marker for rheumatoid arthritis.
Objectives. The aim of this study was to analyze anti-CCP and rheumatoid factor (RF) levels in patients with a hepatitis B and C infection.
Material and Methods. Forty-four patients with hepatitis B, 43 patients with hepatitis C, 25 patients with rheumatoid arthritis, and 46 healthy control serums and their RF and anti-CCP levels were compared. RF was measured by the nephelometer, which detects IgM-RF. Anti-CCP was measured using enzymelinked immunosorbent assay (ELISA) that is included in the second-generation anti-CCP antibody assays (anti-CCP2).
Results. The anti-CCP positivity levels were 20.5%, 32.5%, 72.4% and 10.9% for HBV, HCV and RA groups and healthy control group, respectively. When the groups were compared based on their RF positivity and anti-CCP positivity while the values for HBV and HCV group and healthy control group were the same, in RA group there is a significant difference to the rest of the groups (p < 0.01).
Conclusion. Anti-CCP may be positive for HBV and HCV as well, but it is a sensitive and specific immunological marker for RA diagnosis, especially in high-titres.

Key words

rheumatoid arthritis (RA), hepatitis, anti-CCP

References (21)

  1. Coenen D, Verschueren P, Westhovens R, Bossuyt X. Technical and diagnostic performance of 6 assays for the measurement of citrullinated protein/peptide antibodies in the diagnosis of rheumatoid arthritis. Clin Chem. 2007;53(3):498–504.
  2. Kakumanu P, Yamagata H, Sobel ES, et al. Patients with pulmonary tuberculosis are frequently positive for anti-cyclic citrullinated peptide antibodies, but their sera also react with unmodified arginine-containing peptide. Arthritis Rheum. 2008;58(6):1576–1581.
  3. Kakumanu P, Sobel ES, Narain S, et al. Citrulline dependence of anti-cyclic citrullinated peptide antibodies in systemic lupus erythematosus as a marker of deforming/erosive arthritis. J Rheumatol. 2009;36(12):2682–2690.
  4. Gottenberg JE, Mignot S, Nicaise-Rolland P. Prevalence of anti-cyclic citrullinated peptide and anti-keratin antibodies in patients with primary Sjögren’s syndrome. Ann Rheum Dis. 2005;64(1):114–147.
  5. Ingegnoli F, Galbiati V, Zeni S, et al. Use of antibodies recognizing cyclic citrullinated peptide in the differential diagnosis of joint involvement in systemic sclerosis. Clin Rheumatol. 2007;26(4):510–514.
  6. Takasaki Y, Yamanaka K, Takasaki C, et al. Anticyclic-citrullinated peptide antibodies in patients with mixed connective tissue disease. Mod Rheumatol. 2004;14(5):367–375.
  7. Lima İ, Santiago M. Antibodies against cyclic citrullinated peptides in infectious diseases: A systematic review. Clin Rheumatol. 2010;29:1345–1351.
  8. Kappus MR, Sterling RK. Extrahepatic manifestations of acute hepatitis B virus infection. Gastroenterol Hepatol (NY). 2013;9(2):123–126.
  9. Buzgan T, Karahocagil MK, Irmak H, et al. Clinical manifestations and complications in 1028 cases of brucellosis: A retrospective evaluation and review of the literature. Int J Infect Dis. 2010;14(6):469–478.
  10. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1998;31:315–324.
  11. Aletaha D, Neogi T, Silman AJ, et al. 2010 rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2010;69:1580–1588.
  12. Lee SI, Yoo WH, Yun HJ, et al. Absence of antibody to cyclic citrullinated peptide in sera of nonarthritic patients with chronic hepatitis B virus infection. Clin Rheumatol. 2007;26(7):1079–1082.
  13. Lim MK, Sheen DH, Lee YJ, Mun YR, Park M, Shim SC. Anti-cyclic citrullinated peptide antibodies distinguish hepatitis B virus (HBV)-associated arthropathy from concomitant rheumatoid arthritis in patients with chronic HBV infection. J Rheumatol. 2009;36(4):712–716.
  14. Bassyouni IH, Ezzat Y, Hamdy S, Talaat RM. Clinical significance of anti-cyclic citrullinated peptide antibodies in Egyptian patients with chronic hepatitis C virus genotype IV infection. Clin Chem Lab Med. 2009;47(7):842–847.
  15. Riccio A, Postiglione L, La DP, Spano A, Marzocchella C, Tarantino G. Anti-cyclic citrullinated peptide antibodies in patients affected by HCV-related arthritis. J Biol Regul Homeost Agents. 2008;22(1):57–61.
  16. Zhou RF, Liu XF, Chen Y, Wu F, Zeng AP, Cheng YJ. Detection of antibodies to cyclic citrullinated peptides and its clinical significance in patients with chronic hepatitis B virus infection. Zhonghua Yi XueZaZhi. 2012;12;92(22):1536–1539.
  17. Örge E, Çefle A, Yazıcı A, Gürel Polat N, Hulagu S. The positivity of rheumatoid factor and anti-cyclic citrullinated peptide antibody in nonarthritic patients with chronic hepatitis C. Rheumatol Int. 2010;30:485–488.
  18. Liu FC, Chao YC, Hou TY, et al. Usefulness of anti-CCP antibodies in patients with hepatitis C virus infection with or without arthritis, rheumatoid factor, or cryoglobulinemia. Clin Rheumatol. 2008;27:463–467.
  19. Conrad K, Roggenbuck D, Reinhold D, Dörner T. Profiling of rheumatoid arthritis associated autoantibodies. Autoimmun Rev. 2010;9(6):431–435.
  20. Gokhan A, Turkeyler IH, Babacan T, et al. The antibodies cyclic citrullinated peptides (anti-CCP) positivity could be a promising marker in brucellosis patients presented with peripheric arthritis. Mod Rheumatol. 2014;24(1):182–187.
  21. van Boekel MAM, Vossenaar ER, van den Hoogen FHJ, van Venrooij WJ. Autoantibody systems in rheumatoid arthritis: Specificity, sensitivity and diagnostic value. Arthritis Res. 2002;4:87–93.
© Wroclaw Medical University